Twist Bioscience (TWST) Liabilities and Shareholders Equity (2018 - 2026)

Twist Bioscience has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $676.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.53% year-over-year to $676.2 million; the TTM figure through Mar 2026 stood at $2.6 billion (up 5.83% YoY), while the FY2025 annual figure was $641.9 million, up 4.48% from the prior year.
• Liabilities and Shareholders Equity rose to $676.2 million in Q1 2026, from $638.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for TWST reached as high as $1.0 billion in Q1 2022 and fell as low as $595.6 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $702.8 million (2024), against an average of $753.3 million.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 50.84% — and 2024, when it retreated 21.25%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $910.0 million in 2022, then slipped by 19.47% to $732.8 million in 2023, then fell by 16.95% to $608.6 million in 2024, then climbed by 4.85% to $638.1 million in 2025, then gained by 5.98% to $676.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $676.2 million, $638.1 million, and $641.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.